Skip to main content
Fig. 3 | Journal of Pharmaceutical Health Care and Sciences

Fig. 3

From: Effect of blood pressure control on the risk of proteinuria during bevacizumab treatment in patients with colorectal cancer: a single-center retrospective cohort study

Fig. 3

Landmark analysis performed using each patient’s average SBP status at 3 months. The cumulative incidence was calculated from the 3 month landmark time point. (a) Grade ≥ 2 proteinuria in normal SBP and high SBP groups before and after the landmark time point (p = 0.244 and p = 0.002, respectively). (b) Severe proteinuria in normal SBP and high SBP groups before and after the landmark time point (p = 1.000 and p = 0.015, respectively). Abbreviations: SBP, systolic blood pressure

Back to article page